BioCryst Pharmaceuticals | BCRX - Ordinary Share Capital


BioCryst Pharmaceuticals reported $213.06M in Ordinary Share Capital for its fiscal quarter ending in December of 2025.





Ordinary Share Capital Change Date
Alnylam Pharmaceuticals USD 133.44M 1.07M Mar/2026
BioCryst Pharmaceuticals USD 213.06M 2.54M Dec/2025
Chugai Pharma JPY 1.65B 50K Mar/2026
Daiichi Sankyo JPY 1.85B 9K Dec/2025
DBV Technologies USD 136.82M 51.98K Sep/2025
Enanta Pharmaceuticals USD 212K 1000 Dec/2023
Gilead Sciences USD 1.24B 1000K Mar/2026
GlaxoSmithKline GBP 4.05B 20.6M Mar/2026
Glaxosmithkline GBP 4.08B 49.43M Dec/2025
Incyte USD 199.95M 1.49M Mar/2026
Ionis Pharmaceuticals USD 165.9M 3.93M Mar/2026
Karyopharm Therapeutics USD 18.31M 18.3M Dec/2025
Neurocrine Biosciences USD 100.6M 500K Mar/2026
Novavax USD 162.58M 106K Dec/2025
PTC Therapeutics USD 81.47M 1.54M Dec/2025
Regeneron Pharmaceuticals USD 105M 300K Mar/2026
Roche Holding CHF 795.62M 699.54K Dec/2025
Sarepta Therapeutics USD 105.57M 607K Mar/2026
Ultragenyx Pharmaceutical USD 98.3M 1.7M Mar/2026
Vertex Pharmaceuticals USD 254.2M 200K Mar/2026